SlideShare une entreprise Scribd logo
1  sur  41
Dr Liesl Brown
                                  Senior Lecturer
                                Dept. of Pharmacy
         University of Limpopo (Medunsa Campus)
Module 3.4: Endocrine and Reproductive Pharmacy
   First successful in-vitro fertilization (IVF) done > 3 decades ago (child =
    Louise Joy Brown (DOB: 25 July 1978, weighed: 2.608 kg, UK – became
    pregnant naturally herself in 2006)

   Through technology, it is now possible for a woman:
     to give birth to her own grandchild (surrogacy);
     to have a baby after menopause;
     to have twins born years apart (embryo freezing) and
     to have an ovary transplanted from an aborted fetus


Statements:
 ‘… Seemingly, there is no longer a point at which an infertile couple must
   abandon hope…’ HOPE

   ‘… It is up to infertile couples to rein in their desperation …’ FORGET IT

   ‘… Should having a biologically related child be an undying quest? …’
    MAKE PEACE
Infertility:
   The inability to conceive following 12 months of regular coitus without
    contraception
   In couples who conceive normally, 50% do so following three tries
    whereas about 92% conceive following 12 attempts)
Sterility:
   The etiology of infertility is established and there is no possibility for
    conception


 Primary infertility:                       Secondary infertility:

 Conception has                             At least one previous
 never taken place                          conception has been
                                            documented


                         “Who is affected by infertility?’
     Infertility affects men and women of reproductive age worldwide
    causing considerable personal suffering and disruption of family life
   Globally: 1 in 6 couples (due to sperm dysfunction) (Basin, 2007)
   Sub-Saharan Africa: 30% (male contribution: estimated: 30-50%) (Imade et al.,
    2000)
   Prevalence overseas:
    e.g.  UK: 2 million infertile couples (1 in 9)
            US: 10-15% of all married couples in the US are infertile

   72.4 million women are infertile; of which 40.5 million is seeking infertility medical
    care (estimated on a study done by Boivin et al., 2007)
   Estimates of prevalence: almost 8% - 10% of couples experience some form of
    infertility problem during their reproductive lives (not very accurate, vary from
    region to region)


    40% of infertility - female factor, 40% - male factor, and the remaining 20% -
    mixed male/female factors
   In 10-20% of couples presenting for evaluation, no diagnosis can be made after
    standard investigation (unexplained infertility)
   The etiology of infertility can be divided
                      into three major categories:
                       female factor
                       male factor
                       undetermined etiology

Exogenous causes:                         Endogenous causes:
   STIs e.g. Chlamydia and                  For a couple, assessment of the cause
    gonorrhea                                 is difficult and time consuming
   Abortion                                 Both partners must be investigated
   Drug abuse/Marijuana use                  simultaneously and completely
   Smoking
   Exposure to certain                      In developed countries and in higher
    chemicals, drugs                          socio-economic groups, major
    /environmental toxins                     contributors are:
   Cancer, endometriosis, or                  ovulatory dysfunction
    PCOS                                       advanced maternal age
                                               endometriosis
   Stress
                                               no demonstrable cause
   Poor nutrition
   Intense athletic training
•   Individualized

•   A systematic approach - to evaluate the cause(s) of infertility for a couple

•   Research and innovations in the management of infertility have
    revolutionized the outlook for the infertile couples

•   Now it is possible to offer treatment: 90% - 95% of couples with success
    rates varying between 20% - 80% for various modalities of treatment
• Preliminary assessment
           • Questions: sexual history; durations of cohabitation; sexual
Step 1       problems; menstrual cycle details


         • Investigational plan
           • Should be as complete as possible and include both partners

Step 2     • Physical examination          Laboratory tests - male
                                                            - female


         • Management strategy
           • Pharmacologically induced and normal intervention (sex)
Step 3     • Pharmacologically induced and artificially intervened (ART)
           • Non pharmacological options
• Investigational plan
             Should be as complete as possible and include both partners

             Physical examination                      Laboratory tests
                                           Male                                        Female
         •                                                                             -Ovulation (PCOS)
                                                                                       -Mucus hostility test
                                                                                       -Blood tests
Step 2




         • Semen analysis                                                          Definitions:
                                                                                                                   --
             -First step of investigation
             -Interval of abstinence: 48-72 hrs                  (A)spermia - complete lack of semen
             -collected via masturbation (lab/home)
             -instructions for collections NBNBNBNB!             (Azoo)spermia - absence of sperm cells in semen

         • Normal parameters:                                    (Terato)spermia - sperm with abnormal
             • Sperm concentration (10-6 per ml): 15 (12-16)     morphology
             • Total count: (10-6) per ejaculate): 39 (33-46)    (Asthenozoo)spermia - reduced sperm motility
             • Ejaculated volume (ml): 1.5 (1.4-1.7)
             • Total motile count: (PR + NP, %) : 40 (38-42)     (Oligo)spermia - few spermatozoa in semen
             • Vitality (live spermatozoa, %): 58 (55-63)        (Necrozoo)spermia - total absence of moving
             • Sperm morphology (normal forms, %): 4 (3.0-4.0)   sperm
http://www.flindersivf.com.au/images/malepage/abm_sprm.gif
http://www.biol.tsukuba.ac.jp/~macer/BetCD/Bet8sps.JPG
Description:
Sperm (at center) incubated at 40C shows hyperactive motility (star-spin pattern) while
other sperm cells show progressive or zero motility.   (Fertil. Stertil. 69,118, 1998)


                             http://www.llu.edu/lluhc/fertility
http://syi.hkcampus.net/~syi-kc/sperm.jpg
Step 3
•                             Infertile couple
         •
         •                    Male                   Female                    Other
             •                                                                  Adoption
             • Few cases of male factor                                         Surrogacy
             • reproductive disorders
             • can be remedied
             •
Step 3




             •     Pharmacologically induced                  Pharmacologically induced
             •              plus                                           plus
             •     normal intervention (sex)                  artificial intervention (ART)
             •

             •
             • Induction of ovulation                                   AI
             • Treatment of other conditions                            GIFT
             • Surgery                                                  ICSI
Non-
   Pharmacological
                                           pharmacological

                                            Surgical         Other
                       Pharmacologically
 Pharmacologically
                          induced and
induced and normal
                            artificially
  intervention (sex)                                   Adoption   Surrogacy
                        intervened (ART)
(a) Pharmacological induced and normal intervention (sex)
   Includes drug treatment of: anovulation; endometriosis and the
   treatment of infections e.g. pelvic infections, such as Chlamydia,
   gonorrhea, post-abortal and postpartum infections, PID associated with
   IUDs
                           plus
                  “normal” intercourse



(b) Pharmacologically induced and artificial intervention (ART)
Includes drug treatment of the female
                          plus
                         artificial reproductive techniques
•   The rationale is to drive more than one oocyte to ovulate with each cycle in
    order to increase the odds of a pregnancy

•   Approximately 10-15% of infertile females are anovulatory

•   Causes include:
    • extremes of weight
    • polycystic ovary syndrome (PCOS)
    • emotional stress
    • drugs
    • systemic illness
   A number of medications have been used to help initiate ovulation
    including:
     Clomiphene citrate (CC)
        CC + Dexamethasone

        CC + Bromocriptine

        Levothyroxine sodium (Eltroxin)

        Metformin

     Human menopausal gonadotrophins (hMG)
     Human chorionic gonadotrophin (hCG)
     Bromocriptine
     Glucocorticoids

      Today if lack of ovulation is the only cause operating in a particular
       couple, the chances of conception with treatment equals that of
                            normal fertile population
Clomiphene Citrate (Clomifene citrate) (CC) [SA Essential drug]

       Non-steroidal agent with oestrogenic and anti-oestrogenic properties
       Induces the release of FSH and LH which leads to the maturation of the
        ovarian follicle
       May be used with human chorionic gonadotrophin (hCG)

       Indications:
         Management of anovulatory/oligo-ovulatory infertility in women with
          an intact hypothalamic-pituitary-ovarian axis

    May result in multiple pregnancy, therefore ovarian response should be
              monitored via ultrasound and/or endocrine assays
 Pharmacokinetics                       Contraindications
•     Enterohepatic recirculation       •   Liver disease/history of
                                            hepatic dysfunction
•     t0.5 =5-7 days
                                        •   Ovarian cysts
•     Metabolized in liver
                                        •   Undiagnosed abnormal
•     Eliminated slowly in faeces
                                            uterine bleeding
      via bile
                                    Side effects
    Common:                                      Rare:
    •  Reversible ovarian enlargement            Reversible hair loss
    •  Cyst formation (withdraw Rx)              Hepatotoxicity
    •  Vasomotor flushes
    Uncommon:                                    Uncommon (CNS effects):
    •   Abdominal distension                     Dizziness
    •   Nausea and vomiting                      Nervousness
    •   Breast discomfort                        Depression
    •   Intra-uterine bleeding                   Fatigue
    •   Headache                                 Insomnia
    •   Skin rashes                              Visual disturbances (blurring vision
    •   Weight gain                              diplopia and photophobia
    •
    Dosing regimen:
       50 mg daily for 5 days starting on day 3-5 of a spontaneous or
        induced withdrawal bleed
       If ovulation has occurred, but not conception, use 50 mg again
       Should ovulation failed: 100 mg (single dose) for 5 days
       However, maximum pregnancies are achieved at 50-100 mg dose
       Of these, 5% pregnancies may be multiple almost entirely twins.
        There have been some reports of high order multiple pregnancies


    Success rate:
        Many patients responds on first course
        Inducing ovulation in over 90% of cases
        Pregnancy rates approach only 65%
        80% of patients treated with CC get pregnant within 3 cycles of
         therapy
        In properly selected cases, 80% women can be expected to
         ovulate and approximately 40% become pregnant
   Disadvantages:
Advantages:                                    oMultiple pregnancies (5%
o   Relatively inexpensive                     pregnancies may be twins),
o   Taken by orally                            high order multiple
o   Few side effects (except a                 pregnancies
    multiple gestation rate of 7% in
    anovulatory women and the rare
    possibility of inducing
    hyperstimulation syndrome)
o   The administration of CC early in
    the cycle favors multiple
    follicular recruitment
 Special     prescribers points
   Underlying causes of infertility should be investigated (semen analysis, 1st)
   Failure to respond to 3 courses of clomiphene – go for more
    comprehensive investigations
   Risk : benefit – assessed in patients with endometriosis, fibroid tumour,
    PCOS
   Liver fn – tested prior to therapy initiation
   Risk of multiple pregnancies lowered by monitoring the ovarian response
    (ultrasonographically)
   Warm patients: lightheadedness, visual disturbances, precautions when
    driving or when performing tasks requiring physical skill
(a) Clomiphene Citrate (CC) + Dexamethasone (DEX)
     Patients with hirsutism and high circulating androgen concentrations
      are more resistant to CC

(b) Bromocriptine (BRC)
    Excess prolactin inhibits normal hypothalamic pulsative GnRH release
    Anovulatory women with hyperprolactinaemia (first treated with
     bromocriptine , before considering ovulation induction drugs)

(c) CC + BRC
     Elevated prolactin levels interfere with the normal function of the
      menstrual cycle by suppressing the pulsatile secretion of GnRH. This is
      manifested clinically by ovulatory dysfunction

    BRC is a D-antagonist which directly inhibits pituitary secretion of
     prolactin. It is a highly successful treatment of hyperprolactinaemic
     anovulation

    Results are controversial and extended empirical therapy should be
     avoided
(d) Levothyroxine sodium (Eltroxin)
    •   Hypothyroidism, even if subclinical, should be treated and
        monitored to achieve euthyroid state
    •   Empiric use of thyroid extract or Eltroxin is of no use

(e) Metformin
       It acts by lowering insulin resistance and improved
        peripheral utilization of glucose
       In obese, hirsute women, metformin + diet control = may
        significantly reduce weight + improve results of ovulation
        induction
Used to help induce ovulation
   HMG contain both LH and FSH for ovulation induction
   HMG are found in the urine of postmenopausal women

Indications:
     Clomiphene failures
     Induction of ovulation in women with PCOS and endometriosis
     Women with a pituitary gland that does not produce FSH or LH
     Controlled ovarian hyper stimulation for ART

Dosing regimen:
     IM
     Usually given 2-3 days after menstruation begins, HMG are
      administered daily for 7 to 12 days
     Typical dosage is between 75 and 600 IU/day
Side Effects :
 Hyperovarian stimulation
 Mood swings
Multiple pregnancies by a significant amount (40% of all pregnancies that occur while
using this medication are twins or higher order multiples)


Disadvantages:
     Expensive
     Given daily IM and involves much more risk
     Time consuming and have potential serious side effects
     Over dosage may produce a potentially life-threatening ovarian
      hyperstimulation syndrome


Success rate:
    The multiple gestation rate is about 15-35%
    A 90% anovulation and 50 - 70% pregnancy rate can be expected
    Between 75% and 85% of patients begin to ovulate after using this medication
    Pregnancy rates tend to be around 60%, although half of these pregnancies will
     not be carried to term
     hCG is a peptide hormone that is produced in a pregnant woman's
      placenta (exclusively by trophoblast)
     It helps to maintain the corpus luteum, which produces progesterone and
      oestrogen in order to maintain the first trimester of pregnancy
     hCG is taken from the urine of pregnant women and used to induce
      ovulation in some women

    Mechanism of action:
     Increase the number of eggs that are released from the follicles each month
    It imitates luteinizing hormone (LH), causing your follicles to rupture and
    release eggs (often causes ovaries to release more eggs than normal,
    thereby increasing the chances of becoming pregnant)

Indications:
anovulation
PCOS (polycystic ovarian syndrome)
irregular periods
Directions:
•IM/SC
•Dosages 5,000 to 10,000 units (given a few days before ovulation occurs)
•Dr will monitor follicle and endometrial development through ultrasound
When the follicle size is greater than 18 mm along with simultaneous thickening of endometrium to
more than 8 mm


Injection of hCG to stimulate ovulation (36-48 hours for hCG to begin to work)

(hCG also supports the corpus luteum when given in doses 1500-2000 IU IM on
day 3, 6, 9 post ovulation)


   You and your partner have timed intercourse/IUI
Success rate:
hCG is very successful at inducing ovulation (>90% of anovulatory
women begin to ovulate)
Pregnancy rates are around 15% per cycle
Pregnancy rates increase with the use of IUI


hCG can increase your risk of multiple births


Side Effects:
headache
water retention
fatigue
sore breasts
abdominal discomfort
Irritability
Glucocorticoids
Acts by suppressing ACTH and therefore adrenal androgen
production

Advantages:
      Occasionally helpful in facilitating ovulation because
       circulating androgens cause ovarian follicular atresia

Indications:
        Primarily in PCOS with a component of elevated adrenal
         androgen secretion
        In women with congenital adrenal hyperplasia
Pharmacological management of endometriosis
    Endometriosis is the ectopic growth of endometrium
    Found in  5-10% of the general population
    Noted in 30-40% of women presenting to infertility clinics

Pharmacological management for the treatment of PID infections
    Pelvic infections e.g. Chlamydia, gonorrhea, post-abortal and
     postpartum infections, PID associated with IUD lead to permanent
     structural and functional damage to the fallopian tubes
    Medical treatment can only do the microbial clearance
    Any structural or functional damage is more likely to be permanent

Surgical management
Definition: ART refers to those procedures where gametes (sperm and oocyte)
handling is done in-vitro (outside the body)

Ifinadequate gametogenesis is the cause, couples are offered therapeutic donor
insemination, donor oocytes or both

Artificial insemination (AI):
                             AI is timed to coincide with ovulation, sperm from the
husband or a donor is directed into the vagina, the cervix, near the cervix, or in the
uterus (SR: 30-40% per cycle with cumulative pregnancy rate of 70-80% over 3 cycles)

In vitro fertilization (IVF ): Egg and sperm (of husband and wife or of donors) are
collected and joined in a test tube where fertilization occurs

Gamete Intra-Fallopian Transfer (GIFT ): Eggs of a donor and sperm from
husband/donor is placed in the infertile wife’s fallopian tube (SR: 25-30%)

Intra Cytoplasmic Sperm Injection (ICSI):    Sperm are aspirated directly from the
epididymus or testicles. After egg retrieval, a single sperm is injected into in an oocyte
with the help of micromanipulator instead of leaving the oocytes and sperms together
in a dish for fertilization (SR: comparative to IVF)
http://www.fertilityich.com/images/imgiui.jpg
Surrogacy
Definition:
  A woman who is AI and carries to term a baby who will be raised by his/her
  genetic father and his partner
   The surrogate may be implanted with the husband's sperm and/or the
    wife's egg
   Surrogacy gains in popularity
   Single men also seek surrogate mothers for their children

    Adoption
   Childless singles and couples may want to consider adoption, especially the
    adoption of children who are harder to place e.g.
     with special needs
     sibling groups
     older children

    -Locally / Internationally
  Limited due to the nature of the problem
 Counseling the patient on correct drug use, adverse effects expected ect.

-The need for a counseling service
-The concept of ‘infertility strain’
-Implications support and therapeutic counseling
-The relationship between counselor and doctor
 Being a pillar of support for the infertile couple

 Source of information (e.g. basics of infertility, telephone no. (social
   workers, infertility specialists, counselors etc.)
 Referral to infertility specialists

 Other ???
 Infertility is increasing
 Its impact is underestimated & not understood by
  the main frame of society
 Couples suffering from infertility needs help
  (pharmacologically and psychologically)
 There is hope for some with AI techniques
 Infertility comes with choices
Credit: © Gary Martin/Visuals Unlimited   350631

Ovulation (series 2 of 2.) SEM X1500.
http://www.sirinet.net/~jgjohnso/eggandsperm3.jpg
This spiral represents the 23 stages occurring in the first trimester of pregnancy and
every two weeks of the second and third trimesters. Use the spiral to navigate through
the 40 weeks of pregnancy and preview the unique changes in each stage of human
development. http://www.visembryo.com/baby/
Description
Ultrasound scan of a fetus at 19.5 weeks gestation


       http://www.rba-online.com/

Contenu connexe

Tendances

Modalities of diagnosis in pregnancy
Modalities of diagnosis in pregnancyModalities of diagnosis in pregnancy
Modalities of diagnosis in pregnancyFlavia Dass
 
Management of Female Infertility
Management of Female InfertilityManagement of Female Infertility
Management of Female InfertilitySathish Kumar
 
Female infertility
Female infertilityFemale infertility
Female infertilityberbets
 
Infertility slideshare
Infertility  slideshareInfertility  slideshare
Infertility slidesharedaminipatel37
 
Physiology and Mangement of 2nd stage labour
Physiology and Mangement of 2nd stage labourPhysiology and Mangement of 2nd stage labour
Physiology and Mangement of 2nd stage labourjagadeeswari jayaseelan
 
Female infertility and its management
Female infertility and its managementFemale infertility and its management
Female infertility and its managementSharon Treesa Antony
 
Ante natal clinic - protocol
Ante natal  clinic - protocolAnte natal  clinic - protocol
Ante natal clinic - protocoldrmcbansal
 
Diagnosis of pregnancy
Diagnosis of pregnancyDiagnosis of pregnancy
Diagnosis of pregnancyvruti patel
 
Ventouse or vaccum delivery
Ventouse or vaccum deliveryVentouse or vaccum delivery
Ventouse or vaccum deliveryPriyanka Gohil
 
Uterine malformations
Uterine malformationsUterine malformations
Uterine malformationsAsha Bhat
 
Fetal non stress test
Fetal non stress testFetal non stress test
Fetal non stress testKishan Parekh
 
Uterine abnormalities
Uterine abnormalitiesUterine abnormalities
Uterine abnormalitiesAgnesDavid4
 

Tendances (20)

Causes of infertility
Causes of infertilityCauses of infertility
Causes of infertility
 
Forcep delivery
Forcep deliveryForcep delivery
Forcep delivery
 
Modalities of diagnosis in pregnancy
Modalities of diagnosis in pregnancyModalities of diagnosis in pregnancy
Modalities of diagnosis in pregnancy
 
Management of Female Infertility
Management of Female InfertilityManagement of Female Infertility
Management of Female Infertility
 
Female infertility
Female infertilityFemale infertility
Female infertility
 
Female infertility
Female infertilityFemale infertility
Female infertility
 
Infertility slideshare
Infertility  slideshareInfertility  slideshare
Infertility slideshare
 
Physiology and Mangement of 2nd stage labour
Physiology and Mangement of 2nd stage labourPhysiology and Mangement of 2nd stage labour
Physiology and Mangement of 2nd stage labour
 
Non stress test
Non stress testNon stress test
Non stress test
 
Female infertility and its management
Female infertility and its managementFemale infertility and its management
Female infertility and its management
 
Ante natal clinic - protocol
Ante natal  clinic - protocolAnte natal  clinic - protocol
Ante natal clinic - protocol
 
Diagnosis of pregnancy
Diagnosis of pregnancyDiagnosis of pregnancy
Diagnosis of pregnancy
 
Labour 1st stage
Labour 1st stageLabour 1st stage
Labour 1st stage
 
Ventouse or vaccum delivery
Ventouse or vaccum deliveryVentouse or vaccum delivery
Ventouse or vaccum delivery
 
Management of normal labour
Management ofnormal labourManagement ofnormal labour
Management of normal labour
 
uterine abnormality
uterine abnormalityuterine abnormality
uterine abnormality
 
Uterine malformations
Uterine malformationsUterine malformations
Uterine malformations
 
Infertility
InfertilityInfertility
Infertility
 
Fetal non stress test
Fetal non stress testFetal non stress test
Fetal non stress test
 
Uterine abnormalities
Uterine abnormalitiesUterine abnormalities
Uterine abnormalities
 

Similaire à Infertility And Its Management

Woman Health 2023 PPT.pdf
Woman Health 2023 PPT.pdfWoman Health 2023 PPT.pdf
Woman Health 2023 PPT.pdfWafa sheikh
 
1. INFERTLITY and Menopouse for PG.pptx
1. INFERTLITY and Menopouse for PG.pptx1. INFERTLITY and Menopouse for PG.pptx
1. INFERTLITY and Menopouse for PG.pptxMesfinShifara
 
INFERTILITY AND ITS MANAGEMENT
INFERTILITY AND ITS MANAGEMENTINFERTILITY AND ITS MANAGEMENT
INFERTILITY AND ITS MANAGEMENTPriyanshu Anand
 
Disorder of sexual development revised
Disorder of sexual development revisedDisorder of sexual development revised
Disorder of sexual development revisedASMAA SALAH
 
Diagnosis and management of male infertility
Diagnosis and management of male infertilityDiagnosis and management of male infertility
Diagnosis and management of male infertilityDR SHASHWAT JANI
 
Infertility in male and female.pptx for Nursing students
Infertility in male and female.pptx for Nursing studentsInfertility in male and female.pptx for Nursing students
Infertility in male and female.pptx for Nursing studentsankitarya2550
 
Approach to infertility by dr.bagasi
Approach to infertility by dr.bagasiApproach to infertility by dr.bagasi
Approach to infertility by dr.bagasiAbdulaziz Bagasi
 
Z-L5-B123-RHc(0).pptx
Z-L5-B123-RHc(0).pptxZ-L5-B123-RHc(0).pptx
Z-L5-B123-RHc(0).pptxEnockKizito1
 
when patient refer to ART clinic
when patient refer to ART clinicwhen patient refer to ART clinic
when patient refer to ART clinicDrRokeyaBegum
 
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...Mohd Hanafi
 

Similaire à Infertility And Its Management (20)

Male Infertility
Male InfertilityMale Infertility
Male Infertility
 
Woman Health 2023 PPT.pdf
Woman Health 2023 PPT.pdfWoman Health 2023 PPT.pdf
Woman Health 2023 PPT.pdf
 
1. INFERTLITY and Menopouse for PG.pptx
1. INFERTLITY and Menopouse for PG.pptx1. INFERTLITY and Menopouse for PG.pptx
1. INFERTLITY and Menopouse for PG.pptx
 
INFERTILITY AND ITS MANAGEMENT
INFERTILITY AND ITS MANAGEMENTINFERTILITY AND ITS MANAGEMENT
INFERTILITY AND ITS MANAGEMENT
 
Infertility
InfertilityInfertility
Infertility
 
infertility.pptx
infertility.pptxinfertility.pptx
infertility.pptx
 
Disorder of sexual development revised
Disorder of sexual development revisedDisorder of sexual development revised
Disorder of sexual development revised
 
Diagnosis and management of male infertility
Diagnosis and management of male infertilityDiagnosis and management of male infertility
Diagnosis and management of male infertility
 
2. INFERTILITY.pptx
2. INFERTILITY.pptx2. INFERTILITY.pptx
2. INFERTILITY.pptx
 
Infertility
InfertilityInfertility
Infertility
 
Infertility
Infertility Infertility
Infertility
 
Infertility in male and female.pptx for Nursing students
Infertility in male and female.pptx for Nursing studentsInfertility in male and female.pptx for Nursing students
Infertility in male and female.pptx for Nursing students
 
Infertility
InfertilityInfertility
Infertility
 
Approach to infertility
Approach to infertilityApproach to infertility
Approach to infertility
 
Approach to infertility by dr.bagasi
Approach to infertility by dr.bagasiApproach to infertility by dr.bagasi
Approach to infertility by dr.bagasi
 
Z-L5-B123-RHc(0).pptx
Z-L5-B123-RHc(0).pptxZ-L5-B123-RHc(0).pptx
Z-L5-B123-RHc(0).pptx
 
when patient refer to ART clinic
when patient refer to ART clinicwhen patient refer to ART clinic
when patient refer to ART clinic
 
INFERTILITY.pptx
INFERTILITY.pptxINFERTILITY.pptx
INFERTILITY.pptx
 
Subfertility
SubfertilitySubfertility
Subfertility
 
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
 

Plus de Liesl Brown

Dosage form design for hormonal products (2011)
Dosage form design for hormonal products (2011)Dosage form design for hormonal products (2011)
Dosage form design for hormonal products (2011)Liesl Brown
 
Tut 3412 dosage form design for hormonal products (2011)
Tut 3412 dosage form design for hormonal products (2011)Tut 3412 dosage form design for hormonal products (2011)
Tut 3412 dosage form design for hormonal products (2011)Liesl Brown
 
Eye, Ear And Nose Formulations
Eye, Ear And Nose FormulationsEye, Ear And Nose Formulations
Eye, Ear And Nose FormulationsLiesl Brown
 
Dosage Form Design For Hormonal Products
Dosage Form Design For Hormonal ProductsDosage Form Design For Hormonal Products
Dosage Form Design For Hormonal ProductsLiesl Brown
 
Eye, Ear And Nose Formulations
Eye, Ear And Nose FormulationsEye, Ear And Nose Formulations
Eye, Ear And Nose FormulationsLiesl Brown
 
Cholesterol Screening
Cholesterol ScreeningCholesterol Screening
Cholesterol ScreeningLiesl Brown
 
Blood Pressure Measurement (2011)
Blood Pressure Measurement (2011)Blood Pressure Measurement (2011)
Blood Pressure Measurement (2011)Liesl Brown
 

Plus de Liesl Brown (8)

Dosage form design for hormonal products (2011)
Dosage form design for hormonal products (2011)Dosage form design for hormonal products (2011)
Dosage form design for hormonal products (2011)
 
Tut 3412 dosage form design for hormonal products (2011)
Tut 3412 dosage form design for hormonal products (2011)Tut 3412 dosage form design for hormonal products (2011)
Tut 3412 dosage form design for hormonal products (2011)
 
Eye, Ear And Nose Formulations
Eye, Ear And Nose FormulationsEye, Ear And Nose Formulations
Eye, Ear And Nose Formulations
 
Herbal And THM
Herbal And THMHerbal And THM
Herbal And THM
 
Dosage Form Design For Hormonal Products
Dosage Form Design For Hormonal ProductsDosage Form Design For Hormonal Products
Dosage Form Design For Hormonal Products
 
Eye, Ear And Nose Formulations
Eye, Ear And Nose FormulationsEye, Ear And Nose Formulations
Eye, Ear And Nose Formulations
 
Cholesterol Screening
Cholesterol ScreeningCholesterol Screening
Cholesterol Screening
 
Blood Pressure Measurement (2011)
Blood Pressure Measurement (2011)Blood Pressure Measurement (2011)
Blood Pressure Measurement (2011)
 

Infertility And Its Management

  • 1. Dr Liesl Brown Senior Lecturer Dept. of Pharmacy University of Limpopo (Medunsa Campus) Module 3.4: Endocrine and Reproductive Pharmacy
  • 2. First successful in-vitro fertilization (IVF) done > 3 decades ago (child = Louise Joy Brown (DOB: 25 July 1978, weighed: 2.608 kg, UK – became pregnant naturally herself in 2006)  Through technology, it is now possible for a woman:  to give birth to her own grandchild (surrogacy);  to have a baby after menopause;  to have twins born years apart (embryo freezing) and  to have an ovary transplanted from an aborted fetus Statements:  ‘… Seemingly, there is no longer a point at which an infertile couple must abandon hope…’ HOPE  ‘… It is up to infertile couples to rein in their desperation …’ FORGET IT  ‘… Should having a biologically related child be an undying quest? …’ MAKE PEACE
  • 3. Infertility:  The inability to conceive following 12 months of regular coitus without contraception  In couples who conceive normally, 50% do so following three tries whereas about 92% conceive following 12 attempts) Sterility:  The etiology of infertility is established and there is no possibility for conception Primary infertility: Secondary infertility: Conception has At least one previous never taken place conception has been documented “Who is affected by infertility?’ Infertility affects men and women of reproductive age worldwide causing considerable personal suffering and disruption of family life
  • 4. Globally: 1 in 6 couples (due to sperm dysfunction) (Basin, 2007)  Sub-Saharan Africa: 30% (male contribution: estimated: 30-50%) (Imade et al., 2000)  Prevalence overseas: e.g.  UK: 2 million infertile couples (1 in 9)  US: 10-15% of all married couples in the US are infertile  72.4 million women are infertile; of which 40.5 million is seeking infertility medical care (estimated on a study done by Boivin et al., 2007)  Estimates of prevalence: almost 8% - 10% of couples experience some form of infertility problem during their reproductive lives (not very accurate, vary from region to region)   40% of infertility - female factor, 40% - male factor, and the remaining 20% - mixed male/female factors  In 10-20% of couples presenting for evaluation, no diagnosis can be made after standard investigation (unexplained infertility)
  • 5. The etiology of infertility can be divided into three major categories:  female factor  male factor  undetermined etiology Exogenous causes: Endogenous causes:  STIs e.g. Chlamydia and  For a couple, assessment of the cause gonorrhea is difficult and time consuming  Abortion  Both partners must be investigated  Drug abuse/Marijuana use simultaneously and completely  Smoking  Exposure to certain  In developed countries and in higher chemicals, drugs socio-economic groups, major /environmental toxins contributors are:  Cancer, endometriosis, or  ovulatory dysfunction PCOS  advanced maternal age  endometriosis  Stress  no demonstrable cause  Poor nutrition  Intense athletic training
  • 6. Individualized • A systematic approach - to evaluate the cause(s) of infertility for a couple • Research and innovations in the management of infertility have revolutionized the outlook for the infertile couples • Now it is possible to offer treatment: 90% - 95% of couples with success rates varying between 20% - 80% for various modalities of treatment
  • 7. • Preliminary assessment • Questions: sexual history; durations of cohabitation; sexual Step 1 problems; menstrual cycle details • Investigational plan • Should be as complete as possible and include both partners Step 2 • Physical examination Laboratory tests - male - female • Management strategy • Pharmacologically induced and normal intervention (sex) Step 3 • Pharmacologically induced and artificially intervened (ART) • Non pharmacological options
  • 8. • Investigational plan Should be as complete as possible and include both partners Physical examination Laboratory tests Male Female • -Ovulation (PCOS) -Mucus hostility test -Blood tests Step 2 • Semen analysis Definitions: -- -First step of investigation -Interval of abstinence: 48-72 hrs (A)spermia - complete lack of semen -collected via masturbation (lab/home) -instructions for collections NBNBNBNB! (Azoo)spermia - absence of sperm cells in semen • Normal parameters: (Terato)spermia - sperm with abnormal • Sperm concentration (10-6 per ml): 15 (12-16) morphology • Total count: (10-6) per ejaculate): 39 (33-46) (Asthenozoo)spermia - reduced sperm motility • Ejaculated volume (ml): 1.5 (1.4-1.7) • Total motile count: (PR + NP, %) : 40 (38-42) (Oligo)spermia - few spermatozoa in semen • Vitality (live spermatozoa, %): 58 (55-63) (Necrozoo)spermia - total absence of moving • Sperm morphology (normal forms, %): 4 (3.0-4.0) sperm
  • 11. Description: Sperm (at center) incubated at 40C shows hyperactive motility (star-spin pattern) while other sperm cells show progressive or zero motility. (Fertil. Stertil. 69,118, 1998) http://www.llu.edu/lluhc/fertility
  • 14. Infertile couple • • Male Female Other • Adoption • Few cases of male factor Surrogacy • reproductive disorders • can be remedied • Step 3 • Pharmacologically induced Pharmacologically induced • plus plus • normal intervention (sex) artificial intervention (ART) • • • Induction of ovulation AI • Treatment of other conditions GIFT • Surgery ICSI
  • 15. Non- Pharmacological pharmacological Surgical Other Pharmacologically Pharmacologically induced and induced and normal artificially intervention (sex) Adoption Surrogacy intervened (ART)
  • 16. (a) Pharmacological induced and normal intervention (sex) Includes drug treatment of: anovulation; endometriosis and the treatment of infections e.g. pelvic infections, such as Chlamydia, gonorrhea, post-abortal and postpartum infections, PID associated with IUDs plus “normal” intercourse (b) Pharmacologically induced and artificial intervention (ART) Includes drug treatment of the female plus artificial reproductive techniques
  • 17. The rationale is to drive more than one oocyte to ovulate with each cycle in order to increase the odds of a pregnancy • Approximately 10-15% of infertile females are anovulatory • Causes include: • extremes of weight • polycystic ovary syndrome (PCOS) • emotional stress • drugs • systemic illness
  • 18. A number of medications have been used to help initiate ovulation including:  Clomiphene citrate (CC)  CC + Dexamethasone  CC + Bromocriptine  Levothyroxine sodium (Eltroxin)  Metformin  Human menopausal gonadotrophins (hMG)  Human chorionic gonadotrophin (hCG)  Bromocriptine  Glucocorticoids Today if lack of ovulation is the only cause operating in a particular couple, the chances of conception with treatment equals that of normal fertile population
  • 19. Clomiphene Citrate (Clomifene citrate) (CC) [SA Essential drug]  Non-steroidal agent with oestrogenic and anti-oestrogenic properties  Induces the release of FSH and LH which leads to the maturation of the ovarian follicle  May be used with human chorionic gonadotrophin (hCG)  Indications:  Management of anovulatory/oligo-ovulatory infertility in women with an intact hypothalamic-pituitary-ovarian axis May result in multiple pregnancy, therefore ovarian response should be monitored via ultrasound and/or endocrine assays
  • 20.  Pharmacokinetics  Contraindications • Enterohepatic recirculation • Liver disease/history of hepatic dysfunction • t0.5 =5-7 days • Ovarian cysts • Metabolized in liver • Undiagnosed abnormal • Eliminated slowly in faeces uterine bleeding via bile Side effects Common: Rare: • Reversible ovarian enlargement Reversible hair loss • Cyst formation (withdraw Rx) Hepatotoxicity • Vasomotor flushes Uncommon: Uncommon (CNS effects): • Abdominal distension Dizziness • Nausea and vomiting Nervousness • Breast discomfort Depression • Intra-uterine bleeding Fatigue • Headache Insomnia • Skin rashes Visual disturbances (blurring vision • Weight gain diplopia and photophobia •
  • 21. Dosing regimen:  50 mg daily for 5 days starting on day 3-5 of a spontaneous or induced withdrawal bleed  If ovulation has occurred, but not conception, use 50 mg again  Should ovulation failed: 100 mg (single dose) for 5 days  However, maximum pregnancies are achieved at 50-100 mg dose  Of these, 5% pregnancies may be multiple almost entirely twins. There have been some reports of high order multiple pregnancies  Success rate:  Many patients responds on first course  Inducing ovulation in over 90% of cases  Pregnancy rates approach only 65%  80% of patients treated with CC get pregnant within 3 cycles of therapy  In properly selected cases, 80% women can be expected to ovulate and approximately 40% become pregnant
  • 22. Disadvantages: Advantages: oMultiple pregnancies (5% o Relatively inexpensive pregnancies may be twins), o Taken by orally high order multiple o Few side effects (except a pregnancies multiple gestation rate of 7% in anovulatory women and the rare possibility of inducing hyperstimulation syndrome) o The administration of CC early in the cycle favors multiple follicular recruitment
  • 23.  Special prescribers points  Underlying causes of infertility should be investigated (semen analysis, 1st)  Failure to respond to 3 courses of clomiphene – go for more comprehensive investigations  Risk : benefit – assessed in patients with endometriosis, fibroid tumour, PCOS  Liver fn – tested prior to therapy initiation  Risk of multiple pregnancies lowered by monitoring the ovarian response (ultrasonographically)  Warm patients: lightheadedness, visual disturbances, precautions when driving or when performing tasks requiring physical skill
  • 24. (a) Clomiphene Citrate (CC) + Dexamethasone (DEX)  Patients with hirsutism and high circulating androgen concentrations are more resistant to CC (b) Bromocriptine (BRC)  Excess prolactin inhibits normal hypothalamic pulsative GnRH release  Anovulatory women with hyperprolactinaemia (first treated with bromocriptine , before considering ovulation induction drugs) (c) CC + BRC  Elevated prolactin levels interfere with the normal function of the menstrual cycle by suppressing the pulsatile secretion of GnRH. This is manifested clinically by ovulatory dysfunction  BRC is a D-antagonist which directly inhibits pituitary secretion of prolactin. It is a highly successful treatment of hyperprolactinaemic anovulation  Results are controversial and extended empirical therapy should be avoided
  • 25. (d) Levothyroxine sodium (Eltroxin) • Hypothyroidism, even if subclinical, should be treated and monitored to achieve euthyroid state • Empiric use of thyroid extract or Eltroxin is of no use (e) Metformin  It acts by lowering insulin resistance and improved peripheral utilization of glucose  In obese, hirsute women, metformin + diet control = may significantly reduce weight + improve results of ovulation induction
  • 26. Used to help induce ovulation  HMG contain both LH and FSH for ovulation induction  HMG are found in the urine of postmenopausal women Indications:  Clomiphene failures  Induction of ovulation in women with PCOS and endometriosis  Women with a pituitary gland that does not produce FSH or LH  Controlled ovarian hyper stimulation for ART Dosing regimen:  IM  Usually given 2-3 days after menstruation begins, HMG are administered daily for 7 to 12 days  Typical dosage is between 75 and 600 IU/day
  • 27. Side Effects :  Hyperovarian stimulation  Mood swings Multiple pregnancies by a significant amount (40% of all pregnancies that occur while using this medication are twins or higher order multiples) Disadvantages:  Expensive  Given daily IM and involves much more risk  Time consuming and have potential serious side effects  Over dosage may produce a potentially life-threatening ovarian hyperstimulation syndrome Success rate:  The multiple gestation rate is about 15-35%  A 90% anovulation and 50 - 70% pregnancy rate can be expected  Between 75% and 85% of patients begin to ovulate after using this medication  Pregnancy rates tend to be around 60%, although half of these pregnancies will not be carried to term
  • 28. hCG is a peptide hormone that is produced in a pregnant woman's placenta (exclusively by trophoblast)  It helps to maintain the corpus luteum, which produces progesterone and oestrogen in order to maintain the first trimester of pregnancy  hCG is taken from the urine of pregnant women and used to induce ovulation in some women  Mechanism of action: Increase the number of eggs that are released from the follicles each month It imitates luteinizing hormone (LH), causing your follicles to rupture and release eggs (often causes ovaries to release more eggs than normal, thereby increasing the chances of becoming pregnant) Indications: anovulation PCOS (polycystic ovarian syndrome) irregular periods
  • 29. Directions: •IM/SC •Dosages 5,000 to 10,000 units (given a few days before ovulation occurs) •Dr will monitor follicle and endometrial development through ultrasound When the follicle size is greater than 18 mm along with simultaneous thickening of endometrium to more than 8 mm Injection of hCG to stimulate ovulation (36-48 hours for hCG to begin to work) (hCG also supports the corpus luteum when given in doses 1500-2000 IU IM on day 3, 6, 9 post ovulation)  You and your partner have timed intercourse/IUI
  • 30. Success rate: hCG is very successful at inducing ovulation (>90% of anovulatory women begin to ovulate) Pregnancy rates are around 15% per cycle Pregnancy rates increase with the use of IUI hCG can increase your risk of multiple births Side Effects: headache water retention fatigue sore breasts abdominal discomfort Irritability
  • 31. Glucocorticoids Acts by suppressing ACTH and therefore adrenal androgen production Advantages:  Occasionally helpful in facilitating ovulation because circulating androgens cause ovarian follicular atresia Indications:  Primarily in PCOS with a component of elevated adrenal androgen secretion  In women with congenital adrenal hyperplasia
  • 32. Pharmacological management of endometriosis  Endometriosis is the ectopic growth of endometrium  Found in  5-10% of the general population  Noted in 30-40% of women presenting to infertility clinics Pharmacological management for the treatment of PID infections  Pelvic infections e.g. Chlamydia, gonorrhea, post-abortal and postpartum infections, PID associated with IUD lead to permanent structural and functional damage to the fallopian tubes  Medical treatment can only do the microbial clearance  Any structural or functional damage is more likely to be permanent Surgical management
  • 33. Definition: ART refers to those procedures where gametes (sperm and oocyte) handling is done in-vitro (outside the body) Ifinadequate gametogenesis is the cause, couples are offered therapeutic donor insemination, donor oocytes or both Artificial insemination (AI): AI is timed to coincide with ovulation, sperm from the husband or a donor is directed into the vagina, the cervix, near the cervix, or in the uterus (SR: 30-40% per cycle with cumulative pregnancy rate of 70-80% over 3 cycles) In vitro fertilization (IVF ): Egg and sperm (of husband and wife or of donors) are collected and joined in a test tube where fertilization occurs Gamete Intra-Fallopian Transfer (GIFT ): Eggs of a donor and sperm from husband/donor is placed in the infertile wife’s fallopian tube (SR: 25-30%) Intra Cytoplasmic Sperm Injection (ICSI): Sperm are aspirated directly from the epididymus or testicles. After egg retrieval, a single sperm is injected into in an oocyte with the help of micromanipulator instead of leaving the oocytes and sperms together in a dish for fertilization (SR: comparative to IVF)
  • 35. Surrogacy Definition: A woman who is AI and carries to term a baby who will be raised by his/her genetic father and his partner  The surrogate may be implanted with the husband's sperm and/or the wife's egg  Surrogacy gains in popularity  Single men also seek surrogate mothers for their children Adoption  Childless singles and couples may want to consider adoption, especially the adoption of children who are harder to place e.g.  with special needs  sibling groups  older children -Locally / Internationally
  • 36.  Limited due to the nature of the problem  Counseling the patient on correct drug use, adverse effects expected ect. -The need for a counseling service -The concept of ‘infertility strain’ -Implications support and therapeutic counseling -The relationship between counselor and doctor  Being a pillar of support for the infertile couple  Source of information (e.g. basics of infertility, telephone no. (social workers, infertility specialists, counselors etc.)  Referral to infertility specialists  Other ???
  • 37.  Infertility is increasing  Its impact is underestimated & not understood by the main frame of society  Couples suffering from infertility needs help (pharmacologically and psychologically)  There is hope for some with AI techniques  Infertility comes with choices
  • 38. Credit: © Gary Martin/Visuals Unlimited 350631 Ovulation (series 2 of 2.) SEM X1500.
  • 40. This spiral represents the 23 stages occurring in the first trimester of pregnancy and every two weeks of the second and third trimesters. Use the spiral to navigate through the 40 weeks of pregnancy and preview the unique changes in each stage of human development. http://www.visembryo.com/baby/
  • 41. Description Ultrasound scan of a fetus at 19.5 weeks gestation http://www.rba-online.com/